Litcius/Paper detail

LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC)

M.P. Goetz, M. Toi, J. Huober, J. Sohn, O. Tredan, I.H. Park, M. Campone, S.C. Chen, L.M. Manso Sànchez, Shani- Paluch–Shimon, G. van Hal, A. Shahir, H. Iwata, S. Johnston

2022Annals of Oncology99 citationsDOIOpen Access PDF

Topics & Concepts

MedicineAromatase inhibitorNonsteroidalInternal medicineInterim analysisAromataseInterimOncologyBreast cancerCancerClinical trialArchaeologyHistoryAdvanced Breast Cancer TherapiesNeuroendocrine Tumor Research AdvancesLung Cancer Research Studies
LBA15 MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) | Litcius